Skip to content
DataLookout
Menu

HYPICNCT05961202

The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy

StatusUnknown
PhasePhase 2/3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Eligibility criteria expanded, about 130 wordsv3 Show 7 more changesShow less
    • Primary endpoint revised
    • Primary completion date changed from estimate of Jun 1, 2024 to Sep 1, 2024
    • Study completion date: Jun 1, 2025 to Nov 1, 2025
    • Start date: Jan 1, 2022 to Nov 1, 2021
    • Secondary endpoints: 3 to 6
    • Publications: 3 to 4
    • Study description expanded, about 3 words
  3. Minor Primary completion date: Jan 1, 2024 to Jun 1, 2024v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Composite cardiovascular outcome
Timeframe: 3 years

Secondary (6)

The increase and dynamic changes of LVEF (%)
The increase and dynamic changes of LVIDd (mm)
The decrease and dynamic changes of hs-cTnI (pg/mL)
The decrease and dynamic changes of NT-proBNP (pg/mL)
The decrease and dynamic changes of hs-CRP (mg/L)
Show 1 moreShow less
The decrease and dynamic changes of ESR (mm/H)

Arms and interventions

HCQ groupExperimental

Hydroxychloroquine 200mg qd and Prednisolone 20mg qd for 12 months

Non-HCQ groupActive comparator

Prednisolone 20mg qd for 12 months

Drugs: Hydroxychloroquine, Prednisolone

Sites

1 site in 1 country

  • Tongji HospitalWuhan, Hubei, China